AGCO Recasts Vision to Underscore Its Commitment to Providing Sustainable High-Tech Solutions
AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and solutions, today announced it is highlighting its commitment to bringing farmers sustainable high-tech solutions by relaunching its vision.
“Our new vision—Sustainable high-tech solutions for farmers feeding the world—better represents our thoughtful approach to helping our farmers and our business continually find better and more sustainable ways to raise the food people need, all around the world,” said Martin Richenhagen, President and Chief Executive Officer of AGCO Corporation. “As the world celebrated the 50th anniversary of Earth Day last month, we felt it was the right time to stress the importance of sustainability in our company’s vision.”
Agriculture is one of the most essential industries in the world. As the population grows to a projected 10 billion people by 2050, the potential impact agriculture can have on the health of our planet is tremendous. As a global leader in agriculture, AGCO has a responsibility to help ensure we make a positive impact for the farmers who use our solutions, the communities they feed and the environment we all share.
AGCO precision agriculture tools help farms and machines run more efficiently with lower inputs and higher yields. Sustainable productivity arises through technology, innovation and integrated solutions to grow more food and deliver higher farm income.
Environmental concerns are also driving society’s perception of agriculture, including animal welfare. AGCO is a market leader for cage-free egg equipment and creates solutions to reduce stress and maximize comfort while maintaining healthy animals and encouraging natural behavior.
In short, AGCO’s sustainable high-tech solutions enable farmers to do more with less.
- Advanced farm machines require less fuel and need to make fewer passes in the field, reducing compacted soil and increasing soil fertility.
- Precision technology and agronomic solutions enable farmers to grow and harvest more per acre, making the most of our farmland.
- Better sprayer technology enables farmers to apply products only where needed, reducing inputs to grow healthy food.
- More efficient harvesting equipment means more crops are captured in the field, and better grain and seed storage mean more goes to market.
- Next-generation biosecurity, housing and feeding solutions mean safer, healthier and more productive conditions for swine and poultry.
“We don’t want to stop at meeting the needs of today’s farmers; we must support future generations,” added Eric Hansotia, Chief Operating Officer of AGCO Corporation. “We need to continuously bring to market high-tech solutions to support farmers in producing nutritious food while reducing resource and environmental impacts.”
AGCO (NYSE:AGCO) is a global leader in the design, manufacture and distribution of agricultural solutions and delivers sustainable high-tech solutions for farmers feeding the world through its full line of equipment and related services. AGCO products are sold through five core brands, Challenger®, Fendt®, GSI®, Massey Ferguson® and Valtra®, supported by Fuse® smart farming solutions. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of $9 billion in 2019. For more information, visit http://www.AGCOcorp.com. For company news, information and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.
Global Corporate Communications Manager
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCL and Google Cloud Expand Partnership to Digitally Transform Commerce4.6.2020 16:00:00 CEST | Press release
HCL Technologies (HCL), a leading global technology company, and Google Cloud today announced the expansion of their strategic partnership to bring HCL's software offerings, starting with HCL Commerce, to Google Cloud. Google Cloud will be the preferred cloud platform for HCL Commerce, providing global, secure and elastic infrastructure to power businesses’ eCommerce strategies. Under this partnership, HCL also intends to leverage Anthos to enable multi-cloud and hybrid-cloud deployments of HCL Commerce. HCL Commerce is a leading, cloud-native Commerce platform used by innovative businesses across multiple industries and around the world to drive more than $100 billion in annual client revenues. With a strong track-record of delivering rock-solid performance, scalability and functionality, HCL Commerce today is at the forefront of many organizations’ digital commerce strategies. It stretches far beyond an initial transaction and enables businesses to respond to evolving market conditio
European Commission Grants Marketing Authorisation for DARZALEX ® ▼ (daratumumab) Subcutaneous Formulation for all Currently Approved Daratumumab Intravenous Formulation Indications4.6.2020 16:00:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for DARZALEX®▼(daratumumab) subcutaneous (SC) formulation for the treatment of adult patients with multiple myeloma (MM). Daratumumab SC is administered as a fixed dose, which significantly reduces treatment time, from hours to approximately three to five minutes, when compared to daratumumab intravenous (IV) formulation.1 In addition, only the first dose of daratumumab SC needs to be administered in an environment where resuscitation facilities are available. The approval applies to all current daratumumab indications in frontline and relapsed/refractory settings, and patients currently on daratumumab IV can switch to the SC formulation should they choose to. Data supporting the approval show that daratumumab SC demonstrated a consistent overall response rate (ORR) and a similar safety profile compared with daratumumab IV in patients with rela
AT&T ® México Selects MATRIXX Software for Prepaid Platform Replacement4.6.2020 15:00:00 CEST | Press release
MATRIXX Software today announced that https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.att.com.mx&esheet=52230127&newsitemid=20200604005138&lan=en-US&anchor=AT%26amp%3BT%26%23174%3B+M%26eacute%3Bxico&index=2&md5=52456f1fe4eebcb68026fb5ad3b2dd58 AT&T® México, a subsidiary of AT&T® USA and one of the largest mobile players in the Mexican market, is deploying MATRIXX Software’s cloud native digital commerce platform for its prepaid customers. MATRIXX Digital Commerce is replacing multiple legacy Intelligent Network (IN) and Business Support Systems (BSS) to provide a future-proof, web-scale BSS that will allow for greater innovation and business agility. MATRIXX will support both the AT&T brand and UNEFON brand on a single platform. The industry’s leading solution for real-time cloud native rating and convergent charging for 5G(CCS) and 4G(OCS), MATRIXX Digital Commerce was selected after a rigorous evaluation process that included multiple vendors. “We are proud to be
Moody’s Analytics Forecast: Resurgence of COVID-19 Could Cause Global Economic Depression4.6.2020 14:00:00 CEST | Press release
According to the Moody’s Analytics baseline economic forecast, real global GDP will fall by 4.5% this year as a result of COVID-19. Our base case for the US suggests that it will take until mid-decade for the economy to return to full-employment. Mark Zandi, Chief Economist at Moody’s Analytics, describes the outlook in a new paper, Handicapping the Paths for the Pandemic Economy. “COVID-19 has caused massive damage to the global economy. Quickly reopening economies will boost growth by unleashing pent-up demand, but will also raise the specter of a re-intensification of COVID-19 and another economic downdraft, which could lead to a worldwide depression. We construct our economic forecasts to help market participants navigate this daunting uncertainty and make better decisions,” said Mr. Zandi. The Moody’s Analytics baseline economic forecast represents our view of the most likely trajectory for the global economy. The baseline forecast is part of a set of 12 forecast scenarios, update
Vertex Enhances Integrated Tax Solution for SAP ® Ariba ®4.6.2020 13:13:00 CEST | Press release
Vertex, Inc.,a leading provider of tax technology and services, announced enhancements to its solutions integration with SAP® Ariba® Buying and Invoicing, providing customers with timely, advanced tax insights within their procurement and supply chain processes. Vertex launched an SAP Ariba Tax API and the Vertex Indirect Tax for Procurement with SAP Ariba app extension in 2018, enabling companies to obtain tax calculations from within SAP Ariba Buying and Invoicing, while also supporting the requisition and invoice reconciliation phases of the tax process. This integration with SAP Ariba solutions helps calculate tax at the purchase requisition, invoice reconciliation and final tax determination phases, carrying tax from the purchase requisition to the purchase order. The integrated solution is now enhanced to distinguish between vendor charged, buyer payable, self-assessed and value-added reverse charge taxes, as well as multiple levels of jurisdictions. SAP Ariba solutions provide c
Pierre Fabre Receives European Approval for BRAFTOVI ® (encorafenib) in Combination With Cetuximab for the Treatment of Adult Patients With BRAF V600E -Mutant Metastatic Colorectal Cancer4.6.2020 13:03:00 CEST | Press release
Intended for international media only/not intended for UK- and US-based media This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005490/en/ Pierre Fabre today announced that the European Commission (EC) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as Erbitux®) for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy.1 This approval is based on data from the Phase 3 BEACON CRC trial.1,2 The EC decision is applicable to all 27 EU member states plus Iceland, Liechtenstein, Norway and the United Kingdom.3 “This approval is truly great news and much needed for patients with BRAFV600E-mutant mCRC and for physicians treating this devastating cancer, as until now, there has been no EC-approved therapies specifically indicated for this high-medical-need population,” said Josep Tabernero, MD, PhD, BEACON CRC trial lead inves
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom